Mit Magzter GOLD unbegrenztes Potenzial nutzen

Mit Magzter GOLD unbegrenztes Potenzial nutzen

Erhalten Sie unbegrenzten Zugriff auf über 9.000 Zeitschriften, Zeitungen und Premium-Artikel für nur

$149.99
 
$74.99/Jahr
The Perfect Holiday Gift Gift Now

HOW AI IS CHANGING THE DIAGNOSIS AND CARE OF RARE DISEASES

Healthcare Radius

|

August 2025

In hospitals, labs, and research centers around the world, artificial intelligence (AI) is transforming the way doctors diagnose and treat rare diseases.

- Dr. Amit Saraf, Group Quality Head, Director - Internal Medicine Department, Jupiter Hospital Thane.

HOW AI IS CHANGING THE DIAGNOSIS AND CARE OF RARE DISEASES

Collectively, these conditions affect more than 350 million people globally, yet they remain undetected for years, with patients suffering from symptoms that are misunderstood, misdiagnosed, or ignored. AI is becoming an increasingly useful ally, recognizing elusive patterns, accelerating diagnoses, and facilitating the creation of tailored treatments that seemed impossible until now.

The Singular Challenge of Rare Diseases

Rare diseases are characterized by their low incidence, but as a collective group, they are substantial. Since more than 7,000 rare diseases exist, the vast majority of those affected have long, exasperating odysseys to the correct diagnosis. Rare diseases often present similarly to more frequent ailments, so early detection is challenging with conventional diagnostic techniques. Too often, patients see several specialists, receive a battery of tests, and spend years trying to get an answer. For instance, Ehlers-Danlos syndrome (EDS), a collection of connective tissue disorders, is usually confused with fibromyalgia or psychosomatic pain. Likewise, Fabry disease is usually misdiagnosed as rheumatoid arthritis or gastrointestinal pathology. These delays in diagnosis may result in irreversible complications that range from organ damage to child developmental delay.

Traditional medicine, even with high-tech testing, finds it difficult to provide quick and accurate results. This is where Al promises a ray of hope.

The Potential of Al in Diagnosing Rare Diseases

Quick and Knowledgeable Diagnoses

Al is able to analyze and process enormous amounts of data, from clinical narratives and symptoms to genetic and imaging reports, and spot connections among apparently unrelated bits of information. By highlighting connections that might not be apparent at first glance, Al reduces the amount of time spent thinking about and verifying rare disease diagnoses.

WEITERE GESCHICHTEN VON Healthcare Radius

Healthcare Radius

Healthcare Radius

VENUS REMEDIES GETS DRUG APPROVALS IN VIETNAM

Venus Remedies, a fixed-dosage injectable manufacturer, has secured new marketing authorisations for Methotrexate, Cefuroxime, and Irinotecan in Vietnam.

time to read

1 mins

December 2025

Healthcare Radius

Healthcare Radius

A HEALTHIER INDIA IN THE MAKING: LEADERS DECODE THE ROAD FROM 2025 TO 2026

The collective goal is clear and unanimous: to transition from a system that primarily treats sickness to one that actively promotes lifelong health and well-being.

time to read

12 mins

December 2025

Healthcare Radius

Healthcare Radius

FROM GENES TO CARE: ADVANCING CLINICAL UNDERSTANDING OF HYPOPHOSPHATASIA

From genes to care, the story of hypophosphatasia reminds us that progress in medicine isn't only about scientific discovery, it's about turning knowledge into healing.

time to read

6 mins

December 2025

Healthcare Radius

ALEMBIC PHARMA GETS USFDA NOD FOR DILTIAZEM TABLETS IN THE US

Alembic Pharmaceuticals (Alembic) Aamour announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg.

time to read

1 min

December 2025

Healthcare Radius

Healthcare Radius

ZYDUS GETS USFDA APPROVAL FOR PROSTATE CANCER INJECTABLE

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial (USRLD: Lupron Injection®, 1 mg/0.2 mL).

time to read

1 min

December 2025

Healthcare Radius

Healthcare Radius

SUPERHEALTH LAUNCHES HONEST SECOND OPINION FOR PATIENTS

Superhealth, a zero-wait, commission Superhealth, zerohospital network, announced the launch of \"Honest Second Opinion,\" a service that helps patients make informed decisions about their treatment plans and surgical recommendations.

time to read

1 min

December 2025

Healthcare Radius

Healthcare Radius

KOTAK ALTS INVESTS RS 400MN IN MEDIVERSAL

Kotak Alternate Asset Managers (Kotak Alts), through its Kotak Life Science Fund I, which invests in early to growth-stage life sciences and healthcare businesses, has made an investment of Rs 400 million in Mediversal Healthcare.

time to read

1 min

December 2025

Healthcare Radius

Healthcare Radius

INVIGA HEALTHCARE FUND ACQUIRES 21% STAKE IN FORUS HEALTH

Inviga Healthcare Fund (IHF), the private equity platform founded by Dr B. S. Ajaikumar of HCG, has acquired a 21 per cent stake in Forus Health, an ophthalmic diagnostics company whose devices have screened over 22 million patients across 75+ countries.

time to read

1 min

December 2025

Healthcare Radius

Healthcare Radius

OPTIMISING MATERNITY OPS: REDUCING C-SECTION BURDEN THROUGH EVIDENCE-BASED PROTOCOLS

By building systems that support safety, documentation, and respectful care, institutions can improve outcomes, lower litigation risks, and strengthen quality scores, achieving what healthcare should truly represent: Care Through Trust.”

time to read

7 mins

December 2025

Healthcare Radius

Healthcare Radius

MENTAL HEALTH CARE GOES DIGITAL WITH NEW THERAPY PLATFORM

Following the global observance and continuing the commitment to mental well-being, renowned clinical psychologist Kanika Jindal announced the launch of Harmony Therapy World, a holistic digital platform designed to bring emotional healing and psychological support to people everywhere, privately, compassionately, and without barriers.

time to read

1 min

December 2025

Listen

Translate

Share

-
+

Change font size

Holiday offer front
Holiday offer back